challenging. We sought to compare flow rates and complications among 4 single and double anatomic site transfusion strategies in a swine model of hemorrhagic shock.
, respectively. Average transfusion pressures were 360 mmHg. Infusion rates were as follows: Single Humerus 58.8 ml/min; Sternum 54 ml/min; Sternum + Single Humerus 126 ml/min and Double Humerus 120.3 ml/min. Plasma free hemoglobin levels (baseline, post transfusion) were: Single Humerus 9, 13.2 mg/ml; Sternum 10.5, 18.4 mg/ml; Double Humerus 11.4, 17.8 mg/ml and Sternum + Single Humerus 8.8, 13.9 mg/ml. No significant differences in post transfusion coagulopathy were observed. Blinded pathologist review of pulmonary tissue for edema, inflammation and presence of pulmonary fat emboli between treatment arms is underway.
Conclusions: In an animal model of hemorrhagic shock, double site IO transfusion under a pressure bag appears to confer a significant advantage in flow rates. Proximal humerus and sternal IO transfusions achieved similar flow rates in a model that closely resembles the bone density of an adult male. No significant differences between strategies were noted in regard to intravascular hemolysis or coagulopathy. In cases of severe trauma with challenging vascular access, double site access in either bilateral proximal humerus or sternum and proximal humerus may confer a clinical advantage in speed of transfusion without significant complications.
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This study was in funded in whole by the Department of Navy Bureau of Medicine and Surgery Clinical Investigations Program. Grant # NMCP.2016.0040. Study Objectives: Treatment of opioid overdose in the emergency department is a commonplace event and may serve as an opportunity for patients to transition into long-term treatment of opioid use disorder. However, abrupt opioid cessation results in a severe opioid withdrawal syndrome (OWS) that may motivate patients to use opioids (Rx or illicit) rather than seek further treatment. Lofexidine (LFX) is an alpha2-adrenergic receptor agonist that counteracts the noradrenergic hyperactivity underlying OWS. LFX has been evaluated for treatment of OWS after abrupt withdrawal of shortacting opioids.
Methods: Adults with opioid dependence based on Mini International Neuropsychiatric Interview were randomized (3:3:2) to LFX 2.4 mg (0.6 mg QID), LFX 3.2 mg (0.8 mg QID), or placebo (PBO) QID for 7 days of inpatient treatment. The primary efficacy assessment, per FDA recommendation, was the Short Opiate Withdrawal Scale-Gossop (SOWS-G), a validated, 10-item, patient-reported outcome measure. Secondary efficacy outcomes included Clinical Opiate Withdrawal Scale (COWS) and Objective Opiate Withdrawal Scale (OOWS) of Handelsman scores, which are more commonly used in the clinic and are clinician reported. In addition to the planned analysis for each outcome, Pearson correlation coefficients were calculated post hoc to determine the strength of the relationship between these outcomes.
Results: A total of 602 subjects were randomized and received the study drug. The majority of patients were male, white, and used heroin. Both LFX dose groups were superior to PBO for the primary endpoint, overall reduction in SOWS-G over the 7-day trial (P¼0.017 for LFX 2.4 mg; P¼0.003 for LFX 3.2 mg). Analyses of SOWS-G, COWS, and OOWS by day demonstrated significant score reductions for both LFX groups versus PBO during peak withdrawal (Days 1-4); Day 5 was also significant for SOWS-G and COWS (Table 1 ). All 3 outcomes were highly correlated: SOWS-G to COWS, r¼0.70; SOWS-G to OOWS, r¼0.64; COWS to OOWS, r¼0.81. A significantly greater percentage of subjects in the LFX groups completed the trial versus PBO (42% for 2.4 mg [P¼0.007], 40% for 3.2 mg [P¼0.019], and 28% for PBO).
The most common lofexidine-associated adverse events were orthostatic hypotension, hypotension, and bradycardia, but rarely required study discontinuation (2% per event).
Conclusions: LFX was effective for alleviating symptoms of OWS during the peak of opioid withdrawal, regardless of the outcome measure. The primary outcome, SOWS-G, was highly correlated with COWS and OOWS -2 more familiar measures of OWS severity. LFX-treated subjects were more likely to complete the 7-day inpatient trial. Sympatholytic-related adverse events were common for LFX, but rarely interfered with study completion. LFX, a recently FDA-approved nonopioid medication, may help fill a gap in the treatment of OWS and allow transition to longterm management of opioid use disorder. Study Objectives: To validate a blood test combining ubiquitin C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), at pre-determined cut-off values, to predict traumatic intracranial injuries on head CT scan acutely after mild traumatic brain injury (TBI).
Methods: A total of 1977 TBI subjects were prospectively enrolled among 22 emergency departments in the US and Europe; 1942 (98.2%) had mild TBI (Glasgow Coma Scale [GCS] score 13-15), and 1828 (92.5%) had GCS of 15. Subjects presenting to the ED with suspected TBI underwent blood draw and head CT within 12 hours of injury. Three board-certified neuroradiologists conducted an independent, blinded review of each CT scan to determine whether it was CT-positive or CTnegative with respect to acute intracranial lesions. UCH-L1 and GFAP were measured in serum and analyzed using pre-specified cutoff values of 327pg/mL and 22pg/mL, respectively. UCH-L1 and GFAP assay results were combined into a single brain trauma indicator (BTI) test result that was correlated with CT-detected intracranial injury.
Results: Among mild TBI subjects, the mean age was 48.9 years; 56.6% were male, 30.3% were non-white, and the most frequent injury mechanisms were falls (51.3%) and motor vehicle crashes (34.6%). In mild TBI subjects, the test had sensitivity of 0.975 (95% CI: 0.93, 1.0) and negative predictive value (NPV) of 0.996 (95% CI: 0.99, 1.0). Among the subset of mild TBI subjects with a GCS of 15 the test had sensitivity of 0.968 (0.91, 0.99) and NPV of 0.995 (0.99, 1.0). Test specificity was 0.366 (0.34, 0.39) for mild TBI and 0.370 (0.35, 0.39) for those with a GCS of 15.
Conclusions: The results demonstrated the Banyan BTI TM test is characterized by both high sensitivity and NPV, which supports its potential clinical role for ruling out the need for a CT scan in ED patients with suspected mild TBI and a negative test result.
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